Discover

FMS
Fresenius Medical Care AG
22.81
500 x 22.81
1700 x 22.82
bid
ask
-
0.29
1.26%
10:25 AM
timesize
Ytd-4.24%
1y-11.25%
22.72
day range
22.89
20.02
52 week range
27.64
Open22.91Prev Close23.10Low22.72High22.89Mkt Cap12.16B
Vol58.14KAvg Vol701.19KEPS1.94P/E11.77Forward P/E6.29
Beta0.77Short Ratio3.63Inst. Own9.92%Dividend0.61Div Yield2.61
Ex Div Date05-22Earning11-0350-d Avg23.93200-d Avg23.141yr Est25.77
Earning
DateForEstimateReportedSurprisesurprise %
2026-11-032026-090.61N/AN/AN/A
2026-08-032026-060.620.660.047.14%
2026-05-052026-030.590.53-0.06-10.17%
2026-02-242025-120.650.830.1828.28%
2025-11-042025-090.590.640.058.47%
2025-08-052025-060.50.520.024.00%
Upgrade / Downgrade
DateFirmActionFromTo
2026-08-06BernsteinUpgradeMarket PerformMarket Perform
2025-09-02UBSDowngradeNeutralSell
2025-05-12Truist SecuritiesUpgradeHoldHold
2025-01-06Truist SecuritiesUpgradeHoldHold
2024-10-07Truist SecuritiesUpgradeHoldHold
2024-07-31Truist SecuritiesUpgradeHoldHold
Profile
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-06-29Pzena Investment Management LLC14.99M346.17M3.06%
2026-06-29Morgan Stanley4.35M100.39M0.89%
2026-06-29Dodge & Cox Inc.3.83M88.36M0.78%
2026-06-29Fiduciary Management, Inc.2.94M67.83M0.60%
2026-06-29Brandes Investment Partners L.P.1.92M44.24M0.39%
2026-06-29Millennium Management Llc1.57M36.29M0.32%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-04-29VANGUARD WINDSOR FUNDS-Vanguard Windsor Fund8.20M189.44M1.67%
2026-03-30Dodge & Cox Funds-Dodge & Cox Balanced Fund3.83M88.36M0.78%
2026-04-29VANGUARD WHITEHALL FUNDS-Vanguard Selected Value Fund2.54M58.64M0.52%
2026-06-29Liberty All Star Equity Fund1.13M25.98M0.23%
2026-06-29FMI Funds Inc-Large Cap Fund1.03M23.78M0.21%
2026-06-29John Hancock Capital Series-Classic Value Fund874.36K20.19M0.18%
Dividend
DividendDate
0.864352026-05-22
0.814972025-05-23
0.634152024-05-17
0.61812023-05-17
0.70932022-05-13
0.83382021-05-24
Split
SplitDate
2 : 12012-12-04